| __timestamp | Amphastar Pharmaceuticals, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 125883000 |
| Thursday, January 1, 2015 | 174172000 | 69036000 |
| Friday, January 1, 2016 | 150976000 | 72700000 |
| Sunday, January 1, 2017 | 149380000 | 105700000 |
| Monday, January 1, 2018 | 187681000 | 198700000 |
| Tuesday, January 1, 2019 | 190434000 | 117600000 |
| Wednesday, January 1, 2020 | 206506000 | 108100000 |
| Friday, January 1, 2021 | 238029000 | 122500000 |
| Saturday, January 1, 2022 | 250127000 | 146700000 |
| Sunday, January 1, 2023 | 293274000 | 257500000 |
Unleashing the power of data
In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. This analysis delves into the cost of revenue trends for United Therapeutics Corporation and Amphastar Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Amphastar Pharmaceuticals saw a remarkable 84% increase in its cost of revenue, peaking at approximately $293 million in 2023. Meanwhile, United Therapeutics experienced a 105% surge, reaching around $258 million in the same year.
These trends highlight the dynamic nature of the biopharmaceutical industry, where strategic financial management is key to sustaining growth and innovation.
Cost Insights: Breaking Down Eli Lilly and Company and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down United Therapeutics Corporation and Alkermes plc's Expenses
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Grifols, S.A. and Amphastar Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Vericel Corporation vs Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses